Stefan Greisenegger1, Helen C Segal1, Annette I Burgess1, Debbie L Poole1, Ziyah Mehta1, Peter M Rothwell2. 1. From the Stroke Prevention Research Unit, Nuffield Department of Clinical Neuroscience, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom (S.G., H.C.S., A.I.B., D.L.P., Z.M., P.M.R.); and Department of Neurology, Medical University of Vienna, Vienna, Austria (S.G.). 2. From the Stroke Prevention Research Unit, Nuffield Department of Clinical Neuroscience, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom (S.G., H.C.S., A.I.B., D.L.P., Z.M., P.M.R.); and Department of Neurology, Medical University of Vienna, Vienna, Austria (S.G.). peter.rothwell@ndcn.ox.ac.uk.
Abstract
BACKGROUND AND PURPOSE: Premature death after transient ischemic attack or stroke is more often because of heart disease or cancer than stroke. Previous studies found blood biomarkers not usefully predictive of nonfatal stroke but possibly of all-cause death. This association might be explained by potentially treatable occult cardiac disease or cancer. We therefore aimed to validate the association of a panel of biomarkers with all-cause death, particularly cardiac death and cancer death, despite the absence of associations with risk of nonfatal vascular events. METHODS: Fifteen biomarkers were measured in 929 consecutive patients in a population-based study (Oxford Vascular Study), recruited from 2002 and followed up to 2013. Associations were determined by Cox regression. Model discrimination was assessed by c-statistic and the integrated discrimination improvement. RESULTS: During 5560 patient-years of follow-up, none of the biomarkers predicted risk of nonfatal vascular events. However, soluble tumor necrosis factor α receptor-1, von Willebrand factor, heart-type fatty-acid-binding protein, and N-terminal pro-B-type natriuretic peptide were independently predictive of all-cause death (n=361; adjusted hazard ratio per SD, 95% confidence interval: heart-type fatty-acid-binding protein: 1.31, 1.12-1.56, P=0.002; N-terminal pro-B-type natriuretic peptide: 1.34, 1.11-1.62, P=0.002; soluble tumor necrosis factor α receptor-1: 1.45, 1.26-1.66, P=0.02; von Willebrand factor: 1.19, 1.04-1.36, P=0.01). The independent contribution of the four biomarkers taken together added prognostic information and improved model discrimination (integrated discrimination improvement=0.028, P=0.0001). N-terminal pro-B-type natriuretic peptide was most predictive of vascular death (adjusted hazard ratio=1.80, 95% confidence interval, 1.34-2.41, P<0.0001), whereas heart-type fatty-acid-binding protein predicted cancer deaths (1.64, 1.26-2.12, P=0.0002). Associations were strongest in patients without known prior cardiac disease or cancer. CONCLUSIONS: Several biomarkers predicted death of any cause after transient ischemic attack and minor stroke. N-terminal pro-B-type natriuretic peptide and heart-type fatty-acid-binding protein might improve patient selection for additional screening for occult cardiac disease or cancer, respectively. However, our results require validation in future studies.
BACKGROUND AND PURPOSE: Premature death after transient ischemic attack or stroke is more often because of heart disease or cancer than stroke. Previous studies found blood biomarkers not usefully predictive of nonfatal stroke but possibly of all-cause death. This association might be explained by potentially treatable occult cardiac disease or cancer. We therefore aimed to validate the association of a panel of biomarkers with all-cause death, particularly cardiac death and cancer death, despite the absence of associations with risk of nonfatal vascular events. METHODS: Fifteen biomarkers were measured in 929 consecutive patients in a population-based study (Oxford Vascular Study), recruited from 2002 and followed up to 2013. Associations were determined by Cox regression. Model discrimination was assessed by c-statistic and the integrated discrimination improvement. RESULTS: During 5560 patient-years of follow-up, none of the biomarkers predicted risk of nonfatal vascular events. However, soluble tumor necrosis factor α receptor-1, von Willebrand factor, heart-type fatty-acid-binding protein, and N-terminal pro-B-type natriuretic peptide were independently predictive of all-cause death (n=361; adjusted hazard ratio per SD, 95% confidence interval: heart-type fatty-acid-binding protein: 1.31, 1.12-1.56, P=0.002; N-terminal pro-B-type natriuretic peptide: 1.34, 1.11-1.62, P=0.002; soluble tumor necrosis factor α receptor-1: 1.45, 1.26-1.66, P=0.02; von Willebrand factor: 1.19, 1.04-1.36, P=0.01). The independent contribution of the four biomarkers taken together added prognostic information and improved model discrimination (integrated discrimination improvement=0.028, P=0.0001). N-terminal pro-B-type natriuretic peptide was most predictive of vascular death (adjusted hazard ratio=1.80, 95% confidence interval, 1.34-2.41, P<0.0001), whereas heart-type fatty-acid-binding protein predicted cancer deaths (1.64, 1.26-2.12, P=0.0002). Associations were strongest in patients without known prior cardiac disease or cancer. CONCLUSIONS: Several biomarkers predicted death of any cause after transient ischemic attack and minor stroke. N-terminal pro-B-type natriuretic peptide and heart-type fatty-acid-binding protein might improve patient selection for additional screening for occult cardiac disease or cancer, respectively. However, our results require validation in future studies.
Authors: T B Harris; L Ferrucci; R P Tracy; M C Corti; S Wacholder; W H Ettinger; H Heimovitz; H J Cohen; R Wallace Journal: Am J Med Date: 1999-05 Impact factor: 4.965
Authors: Renate B Schnabel; Xiaoyan Yin; Martin G Larson; Jennifer F Yamamoto; João D Fontes; Sekar Kathiresan; Jian Rong; Daniel Levy; John F Keaney; Thomas J Wang; Joanne M Murabito; Ramachandran S Vasan; Emelia J Benjamin Journal: Arterioscler Thromb Vasc Biol Date: 2013-05-02 Impact factor: 8.311
Authors: Helen C Segal; Annette I Burgess; Debbie L Poole; Ziyah Mehta; Louise E Silver; Peter M Rothwell Journal: Stroke Date: 2014-08-26 Impact factor: 7.914
Authors: Catherine J Augello; Jessica M Noll; Timothy J Distel; Jolita D Wainright; Charles E Stout; Byron D Ford Journal: Brain Res Date: 2018-08-09 Impact factor: 3.252
Authors: Mandip S Dhamoon; Ying-Kuen Cheung; Yeseon P Moon; Clinton B Wright; Joshua Z Willey; Ralph L Sacco; Mitchell S V Elkind Journal: Am J Epidemiol Date: 2017-07-01 Impact factor: 4.897
Authors: Antonela Bicvic; Natalie Scherrer; Juliane Schweizer; Felix Fluri; Mirjam Christ-Crain; Gian Marco De Marchis; Andreas R Luft; Mira Katan Journal: Eur Stroke J Date: 2022-04-20
Authors: Dov Shiffman; Andre R Arellano; Michael P Caulfield; Judy Z Louie; Lance A Bare; James J Devlin; Olle Melander Journal: BMC Cardiovasc Disord Date: 2016-12-07 Impact factor: 2.298
Authors: Héctor Fernández-Susavila; Manuel Rodríguez-Yáñez; Antonio Dopico-López; Susana Arias; María Santamaría; Paulo Ávila-Gómez; Juan M Doval-García; Tomás Sobrino; Ramón Iglesias-Rey; José Castillo; Francisco Campos Journal: J Am Heart Assoc Date: 2017-12-04 Impact factor: 5.501